NCT02896868View on ClinicalTrials.gov

A Study of LY3041658 in Participants With Skin Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 8, 2016

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
Skin DiseasesPsoriasis
Interventions
DRUG

LY3041658

Administered IV.

DRUG

Placebo

Administered IV.

Trial Locations (5)

16635

Altoona Center for Clinical Research, Duncansville

21225

PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore

27710

Duke University Medical Center, Durham

46256

Dawes Fretzin Clinical Research, Indianapolis

91206-4140

Parexel Early Phase Unit at Glendale, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02896868 - A Study of LY3041658 in Participants With Skin Diseases | Biotech Hunter | Biotech Hunter